Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 7/20 | 0.35 |
| ▸ | IL1B | P01584 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 2/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.33 |
| ▸ | HPGDS | O60760 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29326596 | 0.89 | IL1B (0.40) | NLRP3IL1BPIM1PIM2SCN9A | |
| SCHEMBL29326501 | 0.87 | NLRP3 (0.49) | NLRP3IL1BSYKSCN9AFPR2 | |
| SCHEMBL29326505 | 0.87 | NLRP3 (0.49) | NLRP3IL1BSYKSCN9AFPR2 | |
| SCHEMBL29326604 | 0.84 | SCN9A (0.47) | NLRP3IL1BSYKSCN9AHPGDS | |
| SCHEMBL29326508 | 0.81 | NLRP3 (0.48) | NLRP3IL1BSYKPIM1PIM2 | |
| SCHEMBL29326496 | 0.81 | NLRP3 (0.48) | NLRP3IL1BSYKPIM1PIM2 | |
| SCHEMBL29326512 | 0.80 | NLRP3 (0.47) | NLRP3IL1BRAB9ASYK | |
| SCHEMBL29326790 | 0.77 | HPGDS (0.38) | NLRP3IL1BSCN9AHPGDSFPR2 | |
| SCHEMBL26434281 | 0.75 | NLRP3 (0.38) | NLRP3IL1BLMNA | |
| SCHEMBL26434277 | 0.74 | NLRP3 (0.51) | NLRP3IL1BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NLRP3, NLRP1, PYCARD | NLRP3 1/4885IL1B 11/4885RAB9A 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.